Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer
Por:
Rubio-Briones J., Borque A., Esteban L.M., Iborra I., López P.A., Gil J.M., Pallás Y., Fumadó L., Martínez-Breijo S., Chantada V., Gómez E., Quicios C., Congregado C.B., Medina R., Ortiz M., Montesino M., Clar F., Soto J. and Campá J.M.
Publicada:
1 ene 2016
Categoría:
Urology
Resumen:
Objectives: To present a National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
Material and methods: A multicentre observational study (AEU-PIEM/2014/0001) sponsored by the Spanish Association of Urology was conducted using their platform for multicentre studies. The clinical-pathological inclusion criteria were as follows: cT1a-cT3a, PSA <= 20 ng/ml, initial minimum biopsy of 10 cores, number of affected cores <= 3, 1st Gleason score of 3 and 2nd Gleason score <= 4 and a known prostate volume (in cc). A unified follow-up was not established for all recruiting centres; however, a survey was conducted that reflects the follow-up characteristics based on a number of tangible parameters that allow for their comparison. With the same philosophy of flexibility, the use of certain biomarkers and multiparametric MRI was not considered necessary for inclusion.
Results: We describe the Registry's characteristics and possibilities, as well as the preliminary results from the 324 patients included in its first 5 months of operation in the 15 recruiting centres. We also report the clinical-pathological variables, biomarkers, radiodiagnosis technique and quality-of-life questionnaires considered for the database, as well as the possibilities for indefinite follow-up, remaining open to any active treatment recognized in clinical guidelines.
Conclusions: The AEU-PIEM/2014/0001 represents an extremely useful tool for all Spanish urologists for multicentre clinical research. The registry will undoubtedly enable the dissemination of active surveillance of our patients in a more coordinated manner, thus maintaining the advantages of optimised opportunistic screening for prostate cancer without resulting in overtreatment. (C) 2015 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
Rubio-Briones J.:
Instituto Valenciano de Oncología, Valencia, Spain
Borque A.:
Hospital Universitario Miguel Servet, Zaragoza, Spain
Esteban L.M.:
Escuela Universitaria la Almunia, Zaragoza, Spain
Iborra I.:
Instituto Valenciano de Oncología, Valencia, Spain
López P.A.:
Hospital Virgen de la Arrixaca, Murcia, Spain
Gil J.M.:
Hospital Universitario Miguel Servet, Zaragoza, Spain
Pallás Y.:
Hospital de Manises, Valencia, Spain
Fumadó L.:
Hospital del Mar, Barcelona, Spain
Martínez-Breijo S.:
Hospital Juan Canalejo, La Coruña, Spain
Chantada V.:
Hospital Juan Canalejo, La Coruña, Spain
Gómez E.:
Hospital Universitario Reina Sofía, Córdoba, Spain
Quicios C.:
Fundación Jiménez-Díaz, Madrid, Spain
Congregado C.B.:
Hospital Universitario Virgen del Rocío, Sevilla, Spain
Medina R.:
Hospital Universitario Virgen del Rocío, Sevilla, Spain
Ortiz M.:
Hospital General Universitario de Elche, Alicante, Spain
Montesino M.:
Complejo Hospitalario de Navarra, Pamplona, Spain
:
Hospital de la Ribera, Alzira, Valencia, Spain
Soto J.:
Hospital Universitario Puerta del Mar, Cádiz, Spain
Campá J.M.:
Hospital Universitario Araba, Álava, Spain
|